Literature DB >> 29158599

Application of genome editing technologies in rats for human disease models.

Kazuto Yoshimi1,2, Tomoji Mashimo3,4.   

Abstract

Laboratory rats and mice are representative experimental animals for models of human disease. The emergence of genome editing technologies has enabled us to produce a variety of genetically modified animals, including rats, as a means of elucidating the in vivo functions of the gene of interest and characterizing the molecular mechanisms of human disease. Several advanced techniques for knock-in methodologies in rats are currently in development, which permit researchers to introduce precise nucleotide modifications at target sites in the rat's genome. Furthermore, recent studies with knock-out rats have revealed that observed disease phenotypes are often more similar than mouse models to those of humans. In this article, we introduce the methodologies for efficient gene manipulation in rats using genome editing technologies, and describe the advances made using rats for human disease models. We also discuss the importance of gene manipulation in animal models for the better understanding of fundamental processes among different species.

Entities:  

Mesh:

Year:  2017        PMID: 29158599     DOI: 10.1038/s10038-017-0346-2

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  90 in total

1.  An optogenetic toolbox designed for primates.

Authors:  Ilka Diester; Matthew T Kaufman; Murtaza Mogri; Ramin Pashaie; Werapong Goo; Ofer Yizhar; Charu Ramakrishnan; Karl Deisseroth; Krishna V Shenoy
Journal:  Nat Neurosci       Date:  2011-01-30       Impact factor: 24.884

2.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

3.  Improved Genome Editing Efficiency and Flexibility Using Modified Oligonucleotides with TALEN and CRISPR-Cas9 Nucleases.

Authors:  Jean-Baptiste Renaud; Charlotte Boix; Marine Charpentier; Anne De Cian; Julien Cochennec; Evelyne Duvernois-Berthet; Loïc Perrouault; Laurent Tesson; Joanne Edouard; Reynald Thinard; Yacine Cherifi; Séverine Menoret; Sandra Fontanière; Noémie de Crozé; Alexandre Fraichard; Frédéric Sohm; Ignacio Anegon; Jean-Paul Concordet; Carine Giovannangeli
Journal:  Cell Rep       Date:  2016-02-25       Impact factor: 9.423

4.  Targeted genome editing across species using ZFNs and TALENs.

Authors:  Andrew J Wood; Te-Wen Lo; Bryan Zeitler; Catherine S Pickle; Edward J Ralston; Andrew H Lee; Rainier Amora; Jeffrey C Miller; Elo Leung; Xiangdong Meng; Lei Zhang; Edward J Rebar; Philip D Gregory; Fyodor D Urnov; Barbara J Meyer
Journal:  Science       Date:  2011-06-23       Impact factor: 47.728

5.  Epileptic seizures in rats homozygous for two mutations, zitter and tremor.

Authors:  T Serikawa; J Yamada
Journal:  J Hered       Date:  1986 Nov-Dec       Impact factor: 2.645

6.  Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining.

Authors:  Marcello Maresca; Victor Guosheng Lin; Ning Guo; Yi Yang
Journal:  Genome Res       Date:  2012-11-14       Impact factor: 9.043

7.  Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes.

Authors:  Ting Li; Sheng Huang; Xuefeng Zhao; David A Wright; Susan Carpenter; Martin H Spalding; Donald P Weeks; Bing Yang
Journal:  Nucleic Acids Res       Date:  2011-03-31       Impact factor: 16.971

8.  The Rat Genome Database 2015: genomic, phenotypic and environmental variations and disease.

Authors:  Mary Shimoyama; Jeff De Pons; G Thomas Hayman; Stanley J F Laulederkind; Weisong Liu; Rajni Nigam; Victoria Petri; Jennifer R Smith; Marek Tutaj; Shur-Jen Wang; Elizabeth Worthey; Melinda Dwinell; Howard Jacob
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 19.160

9.  Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9.

Authors:  Shota Nakade; Takuya Tsubota; Yuto Sakane; Satoshi Kume; Naoaki Sakamoto; Masanobu Obara; Takaaki Daimon; Hideki Sezutsu; Takashi Yamamoto; Tetsushi Sakuma; Ken-ichi T Suzuki
Journal:  Nat Commun       Date:  2014-11-20       Impact factor: 14.919

10.  CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting.

Authors:  D G Courtney; J E Moore; S D Atkinson; E Maurizi; E H A Allen; D M L Pedrioli; W H I McLean; M A Nesbit; C B T Moore
Journal:  Gene Ther       Date:  2015-08-20       Impact factor: 5.250

View more
  5 in total

Review 1.  Application of CRISPR/Cas9 System in Establishing Large Animal Models.

Authors:  Yingqi Lin; Jun Li; Caijuan Li; Zhuchi Tu; Shihua Li; Xiao-Jiang Li; Sen Yan
Journal:  Front Cell Dev Biol       Date:  2022-05-17

2.  Creation of X-linked Alport syndrome rat model with Col4a5 deficiency.

Authors:  Tomoe Kobayashi; Mayumi Kohno; Masumi Namba; Takayuki Koyano; Takuo Hirose; Masaki Fukushima; Makoto Matsuyama
Journal:  Sci Rep       Date:  2021-10-21       Impact factor: 4.996

Review 3.  Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing.

Authors:  Tianxu Fang; Xiaona Cao; Mysha Ibnat; Guojun Chen
Journal:  J Nanobiotechnology       Date:  2022-08-02       Impact factor: 9.429

4.  Successful production of genome-edited rats by the rGONAD method.

Authors:  Tomoe Kobayashi; Masumi Namba; Takayuki Koyano; Masaki Fukushima; Masahiro Sato; Masato Ohtsuka; Makoto Matsuyama
Journal:  BMC Biotechnol       Date:  2018-04-02       Impact factor: 2.563

5.  Modification of improved-genome editing via oviductal nucleic acids delivery (i-GONAD)-mediated knock-in in rats.

Authors:  Takuya Aoshima; Yukari Kobayashi; Hisayoshi Takagi; Kenta Iijima; Masahiro Sato; Shuji Takabayashi
Journal:  BMC Biotechnol       Date:  2021-11-01       Impact factor: 2.563

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.